Component
Luteolin 4′-O-glucuronide
Context-specific entity; species, compartment and exposure are stated on each claim.
2 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
What acts on it
Human UGT1A9 formed Luteolin 4′-O-glucuronide in the luteolin-conjugation study.
Experimental context and source evidence
- evidence_access
- Primary abstract
- experimental_model
- Recombinant enzymes and UGT1A9-expressing HeLa cells.
- limitations
- Engineered expression; not a human organ concentration.
- nutrient_topic
- Luteolin collection; molecular form, preparation, species, exposure and manipulation remain explicit. · Luteolin / 3′,4′,5,7-tetrahydroxyflavone
- plain_language
- The conjugation position defines a distinct product.
- primary_references
- Breast cancer resistance protein-mediated efflux of luteolin glucuronides in HeLa cells overexpressing UDP-glucuronosyltransferase 1A9. · 2014 · https://pubmed.ncbi.nlm.nih.gov/24092055/ · DOI 10.1007/s11095-013-1207-0
Luteolin: metabolism, immune signaling, redox chemistry and cross-nutrient mechanisms (2026-09-19) · lines 60–66
AI-assisted research curation; primary-abstract references and experimental limitations individually identified. Not publisher full text. · supports · Recombinant enzymes and UGT1A9-expressing HeLa cells. · source_derived_draft · unverified_draft
## luteolin-ugt1a9-4g The conjugation position defines a distinct product. Human UGT1A9 formed Luteolin 4′-O-glucuronide in the luteolin-conjugation study. Model: Recombinant enzymes and UGT1A9-expressing HeLa cells. Limitations: Engineered expression; not a human organ concentration. Evidence access: Primary abstract Breast cancer resistance protein-mediated efflux of luteolin glucuronides in HeLa cells overexpressing UDP-glucuronosyltransferase 1A9. · 2014 · https://pubmed.ncbi.nlm.nih.gov/24092055/ · DOI 10.1007/s11095-013-1207-0
Complete structured claim and evidence
Where it participates (unsigned role)
Ko143 inhibition of ABCG2 reduced luteolin-monoglucuronide efflux and increased intracellular retention.
Experimental context and source evidence
- availability_state
- machinery_impairment Imported condition classification; unverified.
- evidence_access
- Primary abstract
- experimental_model
- UGT1A9-expressing human HeLa cells.
- limitations
- Pharmacological inhibition; diglucuronide compensation was proposed, not proven in patients.
- nutrient_topic
- Luteolin collection; molecular form, preparation, species, exposure and manipulation remain explicit. · Luteolin / 3′,4′,5,7-tetrahydroxyflavone
- plain_language
- Blocking export changes where metabolites accumulate.
- primary_references
- Breast cancer resistance protein-mediated efflux of luteolin glucuronides in HeLa cells overexpressing UDP-glucuronosyltransferase 1A9. · 2014 · https://pubmed.ncbi.nlm.nih.gov/24092055/ · DOI 10.1007/s11095-013-1207-0
- trigger_kind
- machinery_impairment Imported condition classification; unverified.
Luteolin: metabolism, immune signaling, redox chemistry and cross-nutrient mechanisms (2026-09-19) · lines 84–90
AI-assisted research curation; primary-abstract references and experimental limitations individually identified. Not publisher full text. · supports · UGT1A9-expressing human HeLa cells. · source_derived_draft · unverified_draft
## luteolin-abcg2-blockade Blocking export changes where metabolites accumulate. Ko143 inhibition of ABCG2 reduced luteolin-monoglucuronide efflux and increased intracellular retention. Model: UGT1A9-expressing human HeLa cells. Limitations: Pharmacological inhibition; diglucuronide compensation was proposed, not proven in patients. Evidence access: Primary abstract Breast cancer resistance protein-mediated efflux of luteolin glucuronides in HeLa cells overexpressing UDP-glucuronosyltransferase 1A9. · 2014 · https://pubmed.ncbi.nlm.nih.gov/24092055/ · DOI 10.1007/s11095-013-1207-0
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.